Get started

Retesting

BTCUSDT is testing the previous supportThe price had a breakout from the rising wedge as I told in the previous analysis () and after a bounce on the 37300 the price is testing the previous support as new resistance. On the daily timeframe the price goi a rejection from our Daily resistance and supply zone, exactly on 39560. How to approach? We could have a bullish scenario if the price is going to have a breakout from 42k and retest is as new support. In that case, the price will have a breakout from the supply zone and dynamic resistance as well. Otherwise, if the price is going to have a new rejection from the old support (38400-39000) we could see a new breakout from the current support (37k) If the price is going to confirm the breakout, the next valid support is 35k on the weekly one. ––––– Follow the Shrimp 🦐 Keep in mind. 🟣 Purple structure -> Monthly structure. 🔴 Red structure -> Weekly structure. 🔵 Blue structure -> Daily structure. 🟡 Yellow structure -> 4h structure.
Short
by InkyGrip
10
$APM Target PTs 7-14 Long term PT 30 and higherAptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% - 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population. Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week. The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells. Price Action: APM shares are up 30.3% at $1.59 during the premarket session on the last check Thursday. See more from Benzinga FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors EXCLUSIVE: Alfi Inks AI Tech Deal For Improved Passenger Experience At BWI Thurgood Marshall Airport
NASDAQ:APMLong
by BADQOMOCAWGOWLD
1
NEO/USDT Update: Closing the gap to old supportCurrently Neo closes the gap to the old support arounf 40$. We still did not see new ATH which lies around 180$. However, we stay optimistic for this year to reach new ATH after the dust settles from this current pullback. We broke out of the upwards channel and try to get back in again. The volume over 2021 is high which indicates demand. Basic rules: - Never buy the top/ATH - Take profit as long as you can (also partial profit is profit) - Use Stop/loss for leveraged positions - If you are not experienced, don't leverage in the first place Enjoy the ride and don't be too greedy. If you like the content, please like, comment and give this channel a follow. We would love it if you could share your thoughts in the comments. Discussions are very welcome here. Always do your own research and keep in mind that my charts and comments cannot be considered financial advice. Cheers ps. Chart explanation: Main lines: - Green lines are tested support lines. - Orange lines are resistance lines or, if we are above, possible support lines which were not tested yet. - Cyan line is for volume trendline. - White lines are Fibonacci retracement levels Helplines: - Purple lines are trendlines we take a look at. - Yellow lines are for visual help only. Boxes: - Either entry zone or support zone. Check the description.
by tumbler55
2
ZOM to retest the 200ma perhaps?I think the latest days have been amazing for ZOM, Truforma is coming in Q121 and so other solutions in the pipeline, the prospects for the company are very good. This team have been working for years and deserve a better company stock valuation now with their new developed technology. For the short time, I think the stock is likely to retest the 200ma, perhaps around 12ish and consolidate, but I wouldn't get surprise if the stock shoots up to 20 cents or over.
AMEX:ZOMLong
by Allenvik
Still Bullish But It’s A SellSo early I published a bullish flag and then the break out to off to the moon. Well I decided to take the retest even I categorize myself as a breakout trader. At first my psychology had the best of me as I thought I my have entered to early and price reversed and went higher at the beginning of the 11am candle. So scared newbie I closed those positions before the event over $5 in loss. Then at 11:35 price dropped and went into sell as I had predicted originally so I waited til the close of the 11 am candle to confirm the retest. Lesson learned here: be patient, be confident, and let the market come to you. There is nothing to fear but complacency.
Short
by HeyWhit
1